Studi Literatur : Kandidat Obat Baru Dan Target Kerja Obat Penyakit Systemic Lupus Erythematosus
Article Sidebar
Main Article Content
Abstract
Latar Belakang: Systemic lupus erythematosus (SLE) ialah penyakit dengan kerusakan pada sistem kekebalan tubuh, terutama dalam imunitas seluler dan humoral. SLE terjadi pada individu dengan predisposisi genetik, terutama pada gen HLA yang dipicu oleh faktor lingkungan. Pada kebanyakan kasus, SLE muncul akibat efek dari banyak varian gen. Ada banyak golongan obat yang biasa digunakan untuk pengobatan SLE seperti kortikosteroid, imunosupresan, NSAID, atau antibodi monoklonal spesifik yang diarahkan terhadap reseptor permukaan sel atau sitokin Tujuan: memberikan gambaran dan informasi terkini tentang kandidat obat baru dan target kerja obat penyakit lupus. Metode: studi tinjauan pustaka dari Google Scholar, Science Direct, dan PubMed dengan kriteria inklusi dan eksklusi. Hasil target kerja obat tersebut melalui tiga jenis penelitian berupa in vivo, in vitro, dan in silico. Berdasarkan tinjauan pustaka yang sudah dilakukan, terdapat beberapa target kerja obat pada penyakit lupus/SLE yaitu reseptor PI3Kδ, Enzim NF-κB inducing kinase, IFN-γ, IL-3, TNF-α, TP53, VEGFA, IL6, CD4, CCR1, JAK2, XRCC5, XRCC6, RB1, MYC, TP53, IL-1 alpha, IL-5, IL-6, IL-17, Limfotoxin-alpha, IL-21, TLR7, TLR9, CAPS3, STAT3, STAT1, IFNα, FcγR2A, CD22, CD20. Lalu untuk hasil beberapa kandidat obat baru terdapat pada ekstrak daun Bryophyllum pinnatum, curcumin, Langchuangding, Hedyotis diffusa Willd, dan BIIB059. Semua target atau kandidat senyawa pengobatan lupus yang diteliti memiliki hasil yang baik untuk pengobatan lupus.
Kata Kunci : Kandidat Obat Baru, Target Kerja Obat, Systemic Lupus Erythematosus.
Downloads
Article Details
Authors who publish in PharmaCine: Journal of Pharmacy, Medical and Health Science agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-ShareAlike 4.0 International License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
PharmaCine : Journal of Pharmacy, Medical and Health Science by https://journal.unsika.ac.id/ is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
You are free to:
- Share, copy and redistribute the material in any medium or format
- Adapt, remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
References
Thobias IB, Mujawar S, Pardeshi T, Chaudhary S, Batra M, Rao SP, et al. Identification of novel inhibitors for systemic lupus erythematosus by targeting IFN-α and FCγR2A: A structure based pharmacophore approach. Int J Pharm Sci Rev Res. 2015;32(1):175–81.
Lai Y, Ji J, Li Y, Liu J, Lan X, Ge W, et al. Ethyl Acetate Fraction in Hedyotis Diffusa Willd Inhibits T Cell Proliferation to Improve the Pathogenesis of Systemic Lupus Erythematosus. Clin Complement Med Pharmacol. 2021;1(1):100011.
Sigilipu YM, Nurazizah NA, Dewi NP. Inhibitor Kanal Kv1.3: Ekstrak Racun Kalajengking spesies Heterometrus spinnifer (HsTX1) sebagai Terapi Potensial Lupus Eritematosus Sistemik (LES). Scr SCORE Sci Med J. 2022;3(2):151–8.
Toro-Domínguez D, Carmona-Sáez P, Alarcón-Riquelme ME. Support for phosphoinositol 3 kinase and mTOR inhibitors as treatment for lupus using in-silico drug-repurposing analysis. Arthritis Res Ther. 2017;19(1):1–8.
Scuron MD, Fay BL, Connell AJ, Oliver J, Smith PA. The PI3Kδ inhibitor parsaclisib ameliorates pathology and reduces autoantibody formation in preclinical models of systemic lupus erythematosus and Sjӧgren’s syndrome. Vol. 98, International Immunopharmacology. 2021.
Hadi S, Khairunnisa A, Khalifah SN, Oktaviani S, Sari SO, Hapifah UN. Skrining Inhibitor NF-κB Combretum indicum dengan Metode Docking. Vol. 18, Pharmacon: Jurnal Farmasi Indonesia. 2021. p. 157–63.
Brightbill HD, Suto E, Blaquiere N, Ramamoorthi N, Sujatha-Bhaskar S, Gogol EB, et al. NF-κB inducing kinase is a therapeutic target for systemic lupus erythematosus. Vol. 9, Nature Communications. 2018.
Abdoel N, Brun S, Bracho C, Rodríguez MA, Blasini AM. Linker for activation of T cells is displaced from lipid rafts and decreases in lupus T cells after activation via the TCR/CD3 pathway. Clin Immunol. 2012;142(3):243–51.
Mustafa G, Mahrosh HS, Salman M, Sharif S, Jabeen R, Majeed T, et al. Identification of Peptides as Novel Inhibitors to Target IFN-γ, IL-3, and TNF-α in Systemic Lupus Erythematosus. Vol. 2021, BioMed Research International. 2021.
Rodgers DT, Pineda MA, Suckling CJ, Harnett W, Harnett MM. Drug-like analogues of the parasitic worm-derived immunomodulator ES-62 are therapeutic in the MRL/Lpr model of systemic lupus erythematosus. Lupus. 2015;24(13):1437–42.
Furie R, Werth VP, Merola JF, Stevenson L, Reynolds TL, Naik H, et al. Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus. J Clin Invest. 2019;129(3):1359–71.
Handono K, Dantara TWI, Dewi ES, Pratama MZ, Nurdiana N. Bryophyllum pinnatum leaves ethanol extract inhibit maturation and promote apoptosis of systemic lupus erythematosus BALB/c mice B cells. Med J Indones. 2017;26(4):253–60.
Maya A. Pengaruh Ekstrak Bryophillum pinnatum Terhadap Jumlah Sel B Matur dan Kadar Anti dsDNA Pada Mencit BALB/c Model Lupus Bunting. J Kesehat dan Pembang. 2020;10(20):1–9.
Kang P, Wu Z, Zhong Y, Wang Z, Zhou C, Huo S, et al. A Network Pharmacology and Molecular Docking Strategy to Explore Potential Targets and Mechanisms Underlying the Effect of Curcumin on Osteonecrosis of the Femoral Head in Systemic Lupus Erythematosus. Vol. 2021, BioMed Research International. 2021.
Noor A, Assiri A. A novel computational drug repurposing approach for Systemic Lupus Erythematosus (SLE) treatment using Semantic Web technologies. Saudi J Biol Sci. 2021;28(7):3886–92.
Zhou S, Li Q, Zhou S, Zhao M, Lu L, Wu H, et al. A novel humanized cutaneous lupus erythematosus mouse model mediated by IL-21-induced age-associated B cells. J Autoimmun. 2021;123(July):102686.
Li Q, Sun J, Tu J, Li H, Zhang J, Gu H, et al. A Promising Target of Langchuangding Prescription Treating Systemic Lupus Erythaematosus Integrated Network Pharmacology with HPLC-MS and Molecular Docking. 2022;27(11).
Zhuang Y, Zhang X, Luo S, Wei F, Song Y, Lin G, et al. Exploring the Molecular Mechanism of Zhi Bai Di Huang Wan in the Treatment of Systemic Lupus Erythematosus Based on Network Pharmacology and Molecular Docking Techniques. Processes. 2022;10(10).
Yao M, Gao C, Zhang C, Di X, Liang W, Sun W, et al. Identification of Molecular Markers Associated With the Pathophysiology and Treatment of Lupus Nephritis Based on Integrated Transcriptome Analysis. Front Genet. 2020;11(December):1–12.
Wang F, Tasset I, Cuervo AM, Muller S. In Vivo Remodeling of Altered Autophagy-Lysosomal Pathway by a Phosphopeptide in Lupus. Cells. 2020;9(10):1–15.
Rossi EA, Chang CH, Goldenberg DM. Anti-CD22/CD20 bispecific antibody with enhanced trogocytosis for treatment of lupus. PLoS One. 2014;9(5).
Handono K, Sunarti S, Pratama MZ, Hidayat S, Solikhin MB, Sermoati IA, et al. The Mango’s Mistletoe Leaves Extract Ameliorates Lupus by Inhibiting the Anti-dsDNA Antibody Production, the Percentages of CD8+CD28− and CD4+CD28− T Cells. Vol. 10, Open Access Macedonian Journal of Medical Sciences. 2022. p. 248–55.